MENLO PARK, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the closing of its upsized initial public offering of 5,233,765 shares of its Class A common stock, which includes the exercise in full of the underwriters' option to purchase an additional 682,665 shares of Class A common stock at a public offering price of $60.00 per share, less underwriting discounts and commissions. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by BillionToOne, were approximately $314.0 million. BillionToOne's Class A common stock began trading on the Nasdaq Global Select Market on November 6, 2025, under the ticker symbol "BLLN."

J.P. Morgan, Piper Sandler, Jefferies and William Blair acted as joint book-running managers ...